HRP20110801T1 - Tekući oblik fsh - Google Patents

Tekući oblik fsh Download PDF

Info

Publication number
HRP20110801T1
HRP20110801T1 HR20110801T HRP20110801T HRP20110801T1 HR P20110801 T1 HRP20110801 T1 HR P20110801T1 HR 20110801 T HR20110801 T HR 20110801T HR P20110801 T HRP20110801 T HR P20110801T HR P20110801 T1 HRP20110801 T1 HR P20110801T1
Authority
HR
Croatia
Prior art keywords
pharmaceutical form
liquid pharmaceutical
form according
fsh
variant
Prior art date
Application number
HR20110801T
Other languages
English (en)
Croatian (hr)
Inventor
Stolzenberger Sascha
Kohler Erich
Original Assignee
Biogenerix Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogenerix Ag filed Critical Biogenerix Ag
Publication of HRP20110801T1 publication Critical patent/HRP20110801T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HR20110801T 2008-02-08 2009-02-09 Tekući oblik fsh HRP20110801T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08151231 2008-02-08
PCT/EP2009/051451 WO2009098318A1 (en) 2008-02-08 2009-02-09 Liquid formulation of fsh

Publications (1)

Publication Number Publication Date
HRP20110801T1 true HRP20110801T1 (hr) 2011-12-31

Family

ID=40568186

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110801T HRP20110801T1 (hr) 2008-02-08 2009-02-09 Tekući oblik fsh

Country Status (26)

Country Link
US (4) US20110054410A1 (de)
EP (2) EP2412385A1 (de)
JP (1) JP5620824B2 (de)
KR (2) KR101573773B1 (de)
CN (3) CN101970010A (de)
AT (1) ATE523209T1 (de)
AU (1) AU2009211331B2 (de)
BR (1) BRPI0908887B8 (de)
CA (2) CA2926500A1 (de)
CY (1) CY1112082T1 (de)
DE (1) DE202009009905U1 (de)
DK (1) DK2249869T3 (de)
EA (1) EA019530B1 (de)
ES (1) ES2372470T3 (de)
HR (1) HRP20110801T1 (de)
IL (1) IL206759A (de)
ME (1) ME01337B (de)
MX (1) MX2010008802A (de)
NZ (1) NZ586588A (de)
PL (1) PL2249869T3 (de)
PT (1) PT2249869E (de)
RS (1) RS52106B (de)
SI (1) SI2249869T1 (de)
UA (1) UA99337C2 (de)
WO (1) WO2009098318A1 (de)
ZA (1) ZA201004457B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101105871B1 (ko) * 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
RS59913B1 (sr) 2008-10-17 2020-03-31 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
CN102596175A (zh) 2009-07-06 2012-07-18 赛诺菲-安万特德国有限公司 含有甲硫氨酸的水性胰岛素制备物
PT3345593T (pt) 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
MY180661A (en) 2009-11-13 2020-12-04 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
JP5800527B2 (ja) * 2010-03-30 2015-10-28 日東電工株式会社 安定化医薬組成物、安定化医薬組成物溶液製剤、フィルム状製剤及びフィルム状製剤の製造方法
AR081755A1 (es) * 2010-04-02 2012-10-17 Hanmi Holdings Co Ltd Formulacion de accion prolongada de la hormona estimuladora de los foliculos donde se usa un fragmento de inmunoglobulina, metodo de preparacion y metodo para tratar a un sujeto que sufre un trastorno reproductivo
EP2417982A1 (de) * 2010-07-30 2012-02-15 Ferring B.V. Stabilisierung von Gonadotropinen
PL2611458T3 (pl) 2010-08-30 2017-02-28 Sanofi-Aventis Deutschland Gmbh Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087693A1 (es) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
WO2013068525A1 (en) * 2011-11-09 2013-05-16 Adisseo France S.A.S. Pre-slaughter diet including methionine
EP2968391A1 (de) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Langlebige polynukleotidmoleküle
EP3229828B1 (de) 2014-12-12 2023-04-05 Sanofi-Aventis Deutschland GmbH Insulin-glargin/lixisenatid-fixierte verhältnisformulierung
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患之治療
CN105727260A (zh) * 2016-02-03 2016-07-06 华侨大学 一种卵泡刺激素的长效制剂
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
CN105726468A (zh) * 2016-02-28 2016-07-06 中国农业科学院特产研究所 梅花鹿用超数排卵聚乙烯吡咯烷酮fsh复合缓释注射剂
US10085971B2 (en) * 2016-08-22 2018-10-02 Navinta Iii Inc Pharmaceutical solution of asenapine for sublingual or buccal use
CN108728465A (zh) * 2017-04-14 2018-11-02 深圳新诺微环生物科技有限公司 一种表达靶细胞-效应细胞桥接器的微环dna载体及其制备方法和应用
US20230364172A1 (en) * 2022-05-14 2023-11-16 Syncotrance, LLC Modulation of solubility, palatability, absorption, and bioavailability of mitragyna speciosa-derived compounds for oral and buccal delivery

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923805A (en) 1983-11-02 1990-05-08 Integrated Genetics, Inc. Fsh
US4840896A (en) 1983-11-02 1989-06-20 Integrated Genetics, Inc. Heteropolymeric protein
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
CA2018676C (en) 1989-06-20 2003-05-06 Christie A. Kelton Novel heteropolymeric protein production methods
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
DE4440587A1 (de) 1994-11-14 1996-05-15 Fliether Karl Gmbh & Co Basquill-Schloß
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
ES2332931T3 (es) 1997-06-25 2010-02-15 Merck Serono Sa Analogos de hormonas glicoproteinicas entrelazadas por disulfuro, su preparacion y uso.
US20030166525A1 (en) * 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
IL140984A0 (en) * 1998-07-23 2002-02-10 Lilly Co Eli Fsh and fsh variant formulations, products and methods
BRPI0010677B8 (pt) 1999-04-16 2021-05-25 Inst Massone S A processo de purificação de gonadotropinas urinárias humanas a partir de gonadotropinas brutas.
WO2001058493A1 (en) 2000-02-11 2001-08-16 Maxygen Aps Conjugates of follicle stimulating hormones
DE10249817A1 (de) 2002-10-24 2004-05-13 Daimlerchrysler Ag Schaltanordnung zur Betätigung von Beleuchtungssystemen an einem Kraftfahrzeug
DK1610822T4 (en) * 2003-04-02 2019-01-14 Ares Trading Sa Liquid pharmaceutical FSH and LH formulations together with a nonionic surfactant
EP1697412B1 (de) 2003-12-22 2009-10-21 Ares Trading S.A. Methode zur reinigung von fsh
DE602005009856D1 (de) 2004-11-09 2008-10-30 Ares Trading Sa Verfahren zur reinigung von fsh
KR101105871B1 (ko) 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
DK2170942T3 (da) 2007-06-28 2013-11-04 Biogenerix Ag Fsh-producerende celleklon

Also Published As

Publication number Publication date
CY1112082T1 (el) 2015-11-04
SI2249869T1 (sl) 2012-01-31
NZ586588A (en) 2012-10-26
CA2926500A1 (en) 2009-08-13
EA019530B1 (ru) 2014-04-30
ATE523209T1 (de) 2011-09-15
KR101573773B1 (ko) 2015-12-02
BRPI0908887B8 (pt) 2021-05-25
KR20100123697A (ko) 2010-11-24
AU2009211331A1 (en) 2009-08-13
JP2011514317A (ja) 2011-05-06
HK1149494A1 (en) 2011-10-07
IL206759A0 (en) 2010-12-30
CA2713386A1 (en) 2009-08-13
BRPI0908887B1 (pt) 2021-01-19
EP2249869B1 (de) 2011-09-07
ES2372470T3 (es) 2012-01-20
BRPI0908887A2 (pt) 2015-09-15
ZA201004457B (en) 2011-05-25
DK2249869T3 (da) 2011-12-12
US20160303202A1 (en) 2016-10-20
US20160303238A1 (en) 2016-10-20
EP2249869A1 (de) 2010-11-17
ME01337B (me) 2013-12-20
CN104688679A (zh) 2015-06-10
CN101970010A (zh) 2011-02-09
EA201070940A1 (ru) 2010-12-30
MX2010008802A (es) 2011-03-29
UA99337C2 (ru) 2012-08-10
US20160303201A1 (en) 2016-10-20
CN110433136A (zh) 2019-11-12
RS52106B (sr) 2012-08-31
IL206759A (en) 2015-02-26
WO2009098318A1 (en) 2009-08-13
DE202009009905U1 (de) 2009-10-29
KR20150138428A (ko) 2015-12-09
AU2009211331B2 (en) 2014-07-03
PL2249869T3 (pl) 2012-02-29
EP2412385A1 (de) 2012-02-01
KR101662631B1 (ko) 2016-10-05
CA2713386C (en) 2016-04-19
US20110054410A1 (en) 2011-03-03
PT2249869E (pt) 2011-12-16
JP5620824B2 (ja) 2014-11-05

Similar Documents

Publication Publication Date Title
HRP20110801T1 (hr) Tekući oblik fsh
JP6148317B2 (ja) 高眼圧症及び緑内障を治療するための方法及び組成物
AR082024A1 (es) Formulacion de anticuerpo contra ox40l humano
ES2324058T3 (es) Solucion oftalmica de bimatoprost mejorada.
ES2637988T3 (es) Composición farmacéutica de carbetocina
RU2251411C2 (ru) Стабилизированная фармацевтическая композиция в лиофилизированной форме
HRP20120660T1 (hr) Tekuće formulacije lh
WO2013022783A3 (en) Progesterone containing oral dosage forms and related methods
RU2012155711A (ru) Жидкий назальный спрей, содержащий налтрексон в низкой дозе
JP2011502968A5 (de)
HRP20110444T1 (hr) Formulacije paratiroidnih hormona i njihove uporabe
CA2944832A1 (en) Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
CR20210318A (es) Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf
CN102014920B (zh) 滴眼剂制剂及其应用
RU2011122629A (ru) Водная композиция, содержащая фолликулостимулирующий гормон
HRP20120483T1 (hr) Formulacije peg interferona beta
JP5593345B2 (ja) イソプロピルウノプロストンの分解抑制方法
AR085273A1 (es) Formulacion liquida libre de propelente que comprende una droga antimuscarinica
ES2734269T3 (es) Composición que comprende carragenina tipo iota contra conjuntivitis viral
CN108601728A (zh) 包含局部用药物的盖仑制剂
HRP20110085T1 (hr) Fotostabilni farmaceutski pripravci za tretman herpesnog keratitisa koji sadrže brivudin
AU2020353076A1 (en) Pharmaceutical composition comprising thrombolytic peptide-tetrahydroisoquinoline conjugate
US12128054B2 (en) Aqueous pharmaceutical compositions of prostaglandins
RU2013148949A (ru) Местный состав, содержащий кортикостероид в качестве активного ингредиента
KR100945741B1 (ko) 염산아포모르핀을 함유하는 구강스프레이 제제